Literature DB >> 18098131

Improved tracing of hepatitis B virus transmission chains by phylogenetic analysis based on C region sequences.

Hein J Boot1, Jeroen Cremer, Femke D H Koedijk, W Marijn van Ballegooijen, Eline L M Op de Coul.   

Abstract

An effective vaccine is available for the hepatitis B virus (HBV), which is a very contagious human pathogen. The prevalence of chronic HBV infection is very low in the Netherlands (<0.5%), and no universal vaccination is in place. Instead, a program of vaccination for targeted groups at high risk of HBV exposure has been implemented. Because transmission of HBV can occur by various routes, the effectiveness of this targeted vaccination strategy is difficult to assess. Molecular typing data for the surface protein encoding gene of HBV isolates, in combination with epidemiological data, provide some insight into the main transmission routes. Due to the low mutation rate of the HBV genome, many isolates have identical S region sequences, which hampers phylogenetic analysis and identification of transmission chains. The molecular epidemiological analysis of acute HBV isolates based on the surface and core protein encoding regions were compared. The nucleotide diversity found in the C region was statistically significant greater (1.5 times) than in the S region, and phylogenetic analysis based on the C region showed a higher resolution. C region analysis resulted in an almost 50% reduction of genotype A isolates with identical sequences. C region analysis also indicated that no long-chain transmission of genotype D strains is occurring in the Netherlands, as all genotype D isolates have unique C region sequences. Defining the goals of molecular typing of HBV isolates should precede the choice for phylogenetic analysis on the basis of either C or S region sequences. (Copyright) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18098131     DOI: 10.1002/jmv.21080

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Molecular evaluation of hepatitis B virus infection and predominant mutations of pre-core, basal core promoter and S regions in an Iranian population with type 2 diabetes mellitus: a case-control study.

Authors:  Fatemeh Farshadpour; Reza Taherkhani; Fatemeh Saberi
Journal:  BMC Infect Dis       Date:  2022-06-17       Impact factor: 3.667

2.  Ongoing transmission of hepatitis B virus in rural parts of the Netherlands, 2009-2013.

Authors:  Loes C Soetens; Birgit H B van Benthem; Anouk Urbanus; Jeroen Cremer; Kimberly S M Benschop; Ariene Rietveld; Erik I van Dijk; Susan J M Hahné
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

3.  Genetic variation of hepatitis B surface antigen among acute and chronic hepatitis B virus infections in The Netherlands.

Authors:  Jeroen Cremer; Sanne H I Hofstraat; Francoise van Heiningen; Irene K Veldhuijzen; Birgit H B van Benthem; Kimberley S M Benschop
Journal:  J Med Virol       Date:  2018-06-07       Impact factor: 2.327

4.  Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands.

Authors:  Susan Hahné; Robin van Houdt; Femke Koedijk; Marijn van Ballegooijen; Jeroen Cremer; Sylvia Bruisten; Roel Coutinho; Hein Boot
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

5.  Ethical Issues in Genetics and Infectious Diseases Research: An Interdisciplinary Expert Review.

Authors:  Alexis Walker; Vence L Bonham; Angie Boyce; Ellen Wright Clayton; Debra Garcia; Stephanie Johnson; Oliver Laeyendecker; Michelle Lewis; Joseph B Margolick; Debra Mathews; Michael J Parker; Paul Spicer; Chloe L Thio; Gail Geller; Jeffrey Kahn
Journal:  Ethics Med Public Health       Date:  2021-06-07

6.  Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.